Tyrosine

Tyrosine

SCHEMBL3955902

N[C@@H](Cc1ccc(O)cc1)C(=O)O.O=NOO.O=[N+]([O-])O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.65
TPH1 P17752 1/20 0.49
PTGS1 P23219 2/20 0.47
ALPI P09923 1/20 0.47
PKM P14618 1/20 0.47
XIAP P98170 1/20 0.47
HIF1A Q16665 2/20 0.46
KDM4E B2RXH2 1/20 0.46
USP2 O75604 1/20 0.46
EGFR P00533 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
ALOX15 P16050 1/20 0.46
HTR2A P28223 1/20 0.46
PTGS2 P35354 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PCNA P12004 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL3955897 1.00 SLC7A5 (0.65) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL160738 0.90 SLC7A5 (0.80) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL160737 0.90 SLC7A5 (0.80) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL27681068 0.84 SLC7A5 (0.80) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL21800385 0.81 SLC7A5 (0.86) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL7646268 0.81 SLC7A5 (0.92) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL1639829 0.81 SLC7A5 (0.92) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL8024711 0.81 SLC7A5 (0.92) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL10978820 0.81 SLC7A5 (1.00) SLC7A5TPH1PTGS1ALPIPKM
Tyrosine SCHEMBL11676395 0.81 SLC7A5 (1.00) SLC7A5TPH1PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200222492-A1 Method of Reducing Injury to Mammalian Cells NONO INC. (CA) 2020-07-16 US disclosed
US-20180369319-A1 Method of Reducing Injury to Mammalian Cells NONO INC (CA) 2018-12-27 US disclosed
US-20170239316-A1 Method Of Reducing Injury To Mammalian Cells NONO INC (CA) 2017-08-24 US disclosed
US-20150190459-A1 Method Of Reducing Injury To Mammalian Cells NONO INC (CA) 2015-07-09 US disclosed
US-20120302504-A1 Method Of Reducing Injury To Mammalian Cells NONO, INC. (CA) 2012-11-29 US disclosed
US-8071548-B2 Method of reducing injury to mammalian cells NONO, INC. (CA) 2011-12-06 US disclosed
US-20090298747-A1 Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions BIO HOLDING, INC. (US) 2009-12-03 US disclosed
US-20090281037-A1 Method of Reducing Injury to Mammalian Cells NONO INC. (CA) 2009-11-12 US disclosed
US-7510824-B2 Method of screening peptides useful in treating traumatic injury to the brain or spinal cord NONO INC. (CA) 2009-03-31 US disclosed
US-20070224671-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2007-09-27 US disclosed
US-20050059597-A1 Method of reducing injury to mammalian cells 2056954 ONTARIO LTD. (CA) 2005-03-17 US disclosed
US-20040220239-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2004-11-04 US disclosed
US-20040220242-A1 Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions BIO HOLDING, INC. 2004-11-04 US disclosed
US-20040220113-A1 Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions BIO HOLDING, INC. 2004-11-04 US disclosed
US-6489308-B1 ONE AGENT EXHIBITING MAMMALIAN ALPHA 1-ANTITRYPSIN OR ALPHA 1-ANTITRYPSIN-LIKE ACTIVITY, AND A FREE RADICAL SCAVENGER SUCH AS 2,6,8-TRIHYDROXYPURINE, DIHYDRORHODAMINE, OR A COMBINATION THEREOF TRUSTEES OF UNIVERSITY OF TECHNOLOGY CORPORATION 2002-12-03 US disclosed